Logo image
Back
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance
Journal article   Open access   Peer reviewed

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance

M A Pfaller, L Boyken, R J Hollis, S A Messer, S Tendolkar and D J Diekema
Journal of clinical microbiology, Vol.44(3), pp.760-763
03/2006
DOI: 10.1128/JCM.44.3.760-763.2006
PMCID: PMC1393154
PMID: 16517851
url
https://doi.org/10.1128/JCM.44.3.760-763.2006View
Published (Version of record) Open Access

Abstract

Caspofungin is being used increasingly as therapy for invasive candidiasis. Prospective sentinel surveillance for emergence of in vitro resistance to caspofungin among invasive Candida spp. isolates is indicated. We determined the in vitro activity of caspofungin against 8,197 invasive (bloodstream or sterile-site) unique patient isolates of Candida collected from 91 medical centers worldwide from 1 January 2001 to 31 December 2004. We performed antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) M27-A2 method and used a 24-h prominent inhibition endpoint for determination of the MIC. Of 8,197 invasive Candida spp. isolates, species distribution was as follows: 54% Candida albicans, 14% C. glabrata, 14% C. parapsilosis, 11% C. tropicalis, 3% C. krusei, and 4% other Candida spp. Overall, caspofungin was very active against Candida (MIC50/MIC90, 0.03/0.25 microg/ml; 98.2% were inhibited at a MIC of < or = 0.5 microg/ml and 99.7% were inhibited at a MIC of < or = 1 microg/ml). Results by species (expressed as MIC50/MIC90 and the percentage inhibited at < or = 1 microg/ml) were as follows: C. albicans, 0.03/0.06, 99.9; C. glabrata, 0.03/0.06, 99.9; C. parapsilosis, 0.5/0.5, 99.0; C. tropicalis, 0.03/0.06, 99.7; C. krusei, 0.12/0.5, 99.0; and C. guilliermondii, 0.5/1, 94.4. Of the 25 isolates with caspofungin MICs of >1 microg/ml, 12 isolates were C. parapsilosis, 6 isolates were C. guilliermondii, 2 isolates were C. rugosa, and 1 isolate each was C. albicans, C. glabrata, C. krusei, C. lusitaniae, and C. tropicalis. There was no significant change in caspofungin activity over the 4-year study period. Likewise, there was no difference in activity by geographic region. Caspofungin has excellent in vitro activity against invasive clinical isolates of Candida from centers worldwide. Our prospective sentinel surveillance reveals no evidence of emerging caspofungin resistance among invasive clinical isolates of Candida.
 Antifungal Agents - pharmacology Species Specificity Humans Peptides, Cyclic - pharmacology Candidiasis - microbiology Candida - isolation & purification Microbial Sensitivity Tests Candida - classification Time Factors Candidiasis - drug therapy Echinocandins Candida - drug effects In Vitro Techniques Drug Resistance, Fungal Lipopeptides

Details

Metrics

19 Record Views
158 Times Cited - Web of Science
Logo image